Refining lung screening with AI

Many therapeutic decisions in lung cancer are today based on techniques which provide information about the tumor mutational status from next generation sequencing (NGS) and the PD-L1 fraction of the tissue through immunohistochemistry (IHC), among others. Quibim is developing a new solution to work in combination with existing techniques to classify tumor mutational status, predict response to immune checkpoint inhibitors and overall survival from the analysis of the baseline CT scan.

Interested on learning more about QP-Lung?

Contact us